Clinical Trials Logo
  1. Home
  2. Albuminuria
  3. NCT05498116

Effect of Montelukast on Kidney and Vascular Function in Type 1 Diabetes

Albuminuria Clinical Trial

Official title:
Effect of Montelukast on Kidney and Vascular Function in Type 1 Diabetes

Clinical Trial Summary

Kidney disease is a common problem among people with type 1 diabetes and can lead to disability, dialysis, and early death. Inflammation plays a key role in the development of kidney disease in type 1 diabetes and targeting leukotrienes, inflammatory chemicals the body releases in response to allergic reactions, may represent a promising therapy to slow the progression of diabetic kidney disease. The current proposal will investigate whether montelukast, a leukotriene blocker, lowers increased levels of protein in the urine (an early marker of diabetic kidney disease), and improves kidney and cardiovascular function in people with type 1 diabetes and kidney disease.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05498116
Study type Interventional
Source University of Colorado, Denver
Contact Jessica Kendrick
Phone 3037244837
Email Jessica.Kendrick@cuanschutz.edu
Status Recruiting
Phase Phase 4
Start date January 26, 2023
Completion date October 2025
View Details
See also
  Status Clinical Trial Phase
Completed NCT00095290 - Irbesartan Versus Placebo in Combination With Ramipril for Treatment of Albuminuria Phase 4
Completed NCT02144740 - Effect of NWT-03 on Blood Pressure N/A
Completed NCT01041599 - Correlation of Albuminuria With Arterial Stiffness N/A
Active, not recruiting NCT05321095 - Screening for Albuminuria at the First Line for Early Identification of CKD
Completed NCT02945969 - Sodium Lowering and Urinary Protein Reduction Trial Phase 3
Enrolling by invitation NCT04295889 - Towards HOMe-based Albuminuria Screening: an Implementation Study Testing Two Approaches N/A
Recruiting NCT04272359 - Substitution of Sulfonylureas With New Generation of Hypoglycemic Drugs for the Treatment of Type 2 Diabetes Mellitus
Completed NCT03889236 - Dietary Interventions on Glycocalyx Dimensions in South Asian Patients With Diabetic Nephropathy. N/A
Active, not recruiting NCT00625820 - Tetrahydrobiopterin in Patients With Chronic Kidney Disease (CKD) and Albuminuria Phase 2
Recruiting NCT04752293 - Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE)
Completed NCT03118739 - Intensive Uric Acid Lowering With Verinurad and Febuxostat in Patients With Albuminuria Phase 2
Completed NCT06374043 - Decentralized N=1 Study: A Feasible Approach to Evaluate Individual Therapy Response to Dapagliflozin. Phase 4
Completed NCT03396328 - Effects of Intensive Low-Salt Diet Education by Mobile Application on Albuminuria N/A
Not yet recruiting NCT06094920 - Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial Phase 4
Recruiting NCT00342927 - Family Investigation of Nephropathy and Diabetes (F.I.N.D.)
Completed NCT02689778 - Effect of Pirfenidone on Glomerular Filtration Rate and Albuminuria in Patients With Diabetic Nephropathy Phase 3
Completed NCT02497300 - Vascular Effects of Mineralocorticoid Receptor Antagonism in Kidney Disease Phase 2
Completed NCT02446548 - Influence of Aliskiren on Albuminuria After Kidney Transplantation N/A
Completed NCT01547897 - NOX-E36 in Patients With Type 2 Diabetes Mellitus and Albuminuria Phase 2
Enrolling by invitation NCT01316068 - Effect of Sulodexide on Albuminuria in Chinese Type 2 Diabetic Patients Phase 4